Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
This study is ongoing, but not recruiting participants.
Study NCT00053144 Information provided by National Cancer Institute (NCI)
First Received: January 27, 2003 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cytarabine
irinotecan hydrochloride
Additional drug interventions recognized in this trial
Camptothecin
Irinotecan
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
